SARS-CoV-2 spike protein T cell epitopes (S protein epitopes)

SARS-CoV-2 spike protein T cell epitopes are peptide fragments within the viral spike glycoprotein that are recognized by T cells when presented on MHC molecules. Over 2,000 such epitopes have been identified across the spike protein[1], with several regions showing particular immunodominance in mediating protective antiviral immunity[1]. These epitopes are distributed across multiple spike protein structural domains, including the receptor binding domain, N-terminal domain, and S2 subunit[2]. CD4+ T cells targeting these epitopes support B cell antibody responses, while CD8+ T cells mediate direct killing of infected cells[1]. Key immunodominant regions, such as S 864-882, are conserved across emerging SARS-CoV-2 variants and can activate T cells across diverse human leukocyte antigen backgrounds, making them candidates for optimized vaccine design[3]. Rather than serving as direct drug targets, these epitopes are fundamental to understanding vaccine-induced and infection-induced immune protection against COVID-19.

Other names

S protein epitopesSpike glycoprotein T cell epitopesImmunodominant S epitopesS protein-derived peptidesSpike protein-derived T cell antigens

Not applicable for direct drug interactions.